Subcutaneous pump - ProDuodopa - ProDuodopa
The first treatment of its kind in the world, which allows subcutaneous instillation for 24 hours, of levodopa (a derivative of dopamine that is considered the flagship treatment for Parkinson's), without the need for surgery. The treatment is intended for advanced Parkinson's patients for whom the oral (swallow) medication does not provide a satisfactory solution. The treatment was proven to be effective and safe and was approved in the health basket in January 2023.
Prodevodopa is intended for the treatment of Parkinson's disease in an advanced stage, which responds to treatment with levodopa, accompanied by severe motor fluctuations and hypermobility, or involuntary movement disorders, when existing combinations of medical preparations for the treatment of Parkinson's were not effective.
Ferodopa is a drug that increases the level of dopamine in the body and thus reduces the symptoms of the disease, it combines two components:
- Foslevodopa 240 mg/ml - helps relieve the symptoms of Parkinson's disease by increasing the amount of dopamine in the brain
- Foscarbidopa Foscarbidopa 12 mg/ml - inhibits the breakdown of foscarbidopa, thereby improving its effect and reducing its side effects.
Produodopa is administered by a pump that infuses the drug into the subcutaneous layer through a tube connected on one side to the pump and on the other side to the skin (so no surgery is necessary).
The pump makes it possible to determine a personal and precise dosage for each patient according to his needs, when different dosages can be used throughout the day: dosage for the day, for the night, for physical activity... The administration of the treatment by the pump simulates the physiological state of the body, by infusing the medicine continuously, 24 hours a day.
* The brothers and sisters team of ABVIE CARE Guides patients in the use, supports Provodopa patients and accompanies them and their treatment supporters throughout the period of Provodopa use.
The efficacy and safety of provodopa was tested in two phase 3 studies, for 12 weeks and 52 weeks.
In a 52-week study conducted among 244 patients, the following were observed:
- Average increase in almost 4 hours "ON" without dyskinesia
- Average descent in about 3.5 hours "OFF"
- A significant decrease in the percentage of patients waking up in the morning with akinesia (OFF mode)
The most common adverse events (≥10%) were infusion site reactions (erythema, cellulitis, nodules, pain, edema, infusion site reaction and infection), hallucinations, falls, and anxiety.
